Diaceutics (LON:DXRX) Insider Nick Roberts Buys 91 Shares of Stock

Diaceutics PLC (LON:DXRX) insider Nick Roberts acquired 91 shares of the stock in a transaction on Wednesday, October 1st. The shares were purchased at an average price of GBX 165 per share, for a total transaction of £150.15.

Diaceutics Price Performance

DXRX stock opened at GBX 165 on Friday. The stock has a market capitalization of £139.50 million, a price-to-earnings ratio of -8,168.32 and a beta of 0.58. Diaceutics PLC has a fifty-two week low of GBX 106 and a fifty-two week high of GBX 167. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. The business’s fifty day moving average price is GBX 143.24 and its two-hundred day moving average price is GBX 129.57.

Diaceutics (LON:DXRX) last released its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. On average, equities analysts anticipate that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Royal Bank Of Canada reduced their target price on Diaceutics from GBX 195 to GBX 185 and set an “outperform” rating on the stock in a report on Thursday, July 10th. Canaccord Genuity Group reissued a “buy” rating and set a GBX 180 target price on shares of Diaceutics in a report on Tuesday, July 22nd. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics currently has a consensus rating of “Buy” and an average target price of GBX 175.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.